# Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

Source: https://onco.cc/trials/nct06927986/  
OnCo record `nct06927986` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing SYS6010 in non-small-cell lung cancer, now recruiting.

## Summary

Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01） is a phase 3 interventional study registered as NCT06927986, led by CSPC Megalith Biopharmaceutical, and recruiting on the registry. Official title: A Randomised, Open-label, Multi-centre, Phase III Clinical Study Comparing SYS6010 With Platinum-based Chemotherapy in the Treatment of EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of EGFR TKI Treatment. Planned enrolment is 380 participants (estimated). The study started in 2025-03-30 and primary completion is expected in 2026-07-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: SYNSTAR01
- Tags: ctgov-ingest
- Registry id: NCT06927986
- Phase: 3
- Setting: A Randomized, Open-label, Multi-center, Phase III Clinical Study Comparing SYS6010 With Platinum-based Chemotherapy in the Treatment of EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of EGFR TKI Treatment
- Sponsor: CSPC Megalith Biopharmaceutical
- Enrolled: 380

## Sources

- ClinicalTrials.gov NCT06927986: https://clinicaltrials.gov/study/NCT06927986

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [SYS6010](https://onco.cc/drugs/sys6010/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)

---
JSON: https://onco.cc/api/v1/entities/nct06927986.json